sa.achebe98/100
Cross-check: PeptideMeter and Medutest, same lot, agreement to 0.1 points. Both agree with the declared figure. No excipient. Cake intact.
GL Biochem — GL Biochem (Shanghai) Ltd.
Shanghai, CN · established 1998. The index holds 83 assay reports across 17 batches and 14 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where GL Biochem sells
GL Biochem (Shanghai) Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit GL Biochem at glbiochem.net →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- GL Biochem (Shanghai) Ltd.
- Short code in this index
- GL Biochem
- Also known as
- GL Biochem · GLS
- Domain
- glbiochem.net →
- City
- Shanghai
- Region
- Shanghai
- Country
- CN
- Established
- 1998
- First record in index
- 19 Jul 2024
- Most recent record
- 19 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
16.9%
n=83
Retail, shipped to the buyer
66.3%
n=83
Direct to the laboratory
10.8%
n=83
Median courier leg, direct despatch
8d
n=9
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 14 | 16.9% |
| Retail purchase, shipped to the buyer | 43 | 51.8% |
| Retail purchase via a third-party forwarder | 12 | 14.5% |
| Supplier despatch direct to the laboratory | 9 | 10.8% |
| Laboratory retained-sample archive | 5 | 6.0% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 83 GL Biochem records the index holds, 14 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 7 of the 14 compounds GL Biochem is represented by here — Semax, BPC-157, Kisspeptin-10, MK-677 (Ibutamoren mesylate), SS-31 (Elamipretide), Tirzepatide and 1 further compound. Those are the GL Biochem lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
No contributor to this index has named a regional stock location for GL Biochem. 14 of its records nevertheless arrived by a domestic-warehouse route, so stock is held somewhere; the index does not know where and will not guess.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is GL Biochem's own reviewers: 5 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. Where GL Biochem despatched a sample direct to a laboratory, the courier leg ran a median 8 days across 9 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.81%
n=83
Interquartile range
0.53pp
n=83
10th percentile
98.02%
n=83
Pass rate vs index spec
94.0%
n=83
Median recovery vs claim
97.7%
n=47
Median water
4.71%
n=83
Median |mass error|
2.4ppm
n=69
Records carrying a flag
67.5%
n=83
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.54pp
n=10
Index median spread
0.67pp
n=28
Lots tested 3+ times
10
n=17
Across the 10 GL Biochem lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.54 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
-0.03pp
n=17
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
41%
n=17
Divergences beyond 1 pp
0%
n=17
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.77%
n=69
Supplier-supplied median
98.97%
n=9
Supplier-supplied share of records
10.8%
n=83
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of GL Biochem batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
71/100
n=17
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 53% | 25 points | |
| Peptide content stated | 47% | 20 points | |
| Endotoxin stated | 35% | 15 points | |
| Named impurities rather than a total | 27% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 18 | 98.88 | 98.55 | +0.33 | 97.0 | 94 |
| Kisspeptin-10 | Melanocortin-receptor | 9 | 98.71 | 99.28 | -0.57 | 98.5 | 100 |
| L-Carnosine | Short | 9 | 99.60 | 99.58 | +0.02 | 99.0 | 100 |
| BPC-157 | Tissue-repair | 8 | 98.59 | 99.16 | -0.56 | 98.0 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 8 | 98.88 | 99.49 | -0.61 | 98.5 | 100 |
| Semax | Neuroactive | 7 n=7 | 99.09 | 99.46 | -0.37 | 98.5 | 100 |
| Semaglutide | Incretin | 6 n=6 | 98.06 | 98.89 | -0.83 | 97.0 | 100 |
| SS-31 (Elamipretide) | Metabolic | 5 n=5 | 98.33 | 99.53 | -1.20 | 98.5 | 40 |
| Exenatide | Incretin | 4 n=4 | 98.42 | 98.98 | -0.56 | 98.0 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 3 n=3 | 98.78 | 99.38 | -0.60 | 98.5 | 100 |
| L-Glutathione (reduced) | Short | 2 n=2 | n<3 | 99.33 | — | 98.5 | 100 |
| GHK-Cu | Tissue-repair | 2 n=2 | n<3 | 98.56 | — | 97.0 | 100 |
| GHRP-6 | Growth-hormone | 1 n=1 | n<3 | 99.54 | — | 99.0 | 100 |
| CJC-1295 (no DAC) | Growth-hormone | 1 n=1 | n<3 | 99.09 | — | 98.0 | 0 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 39 | 98.77 | +0.00 | 98.77 |
| PeptideMeter | 20 | 98.68 | -0.05 | 98.73 |
| Medutest | 10 | 99.47 | +0.08 | 99.39 |
| VendorInvestigate | 4 | 98.67 | -0.11 | 98.78 |
| Nordanalyt | 7 | 98.93 | +0.02 | 98.91 |
| Kestrel | 3 | 99.05 | +0.24 | 98.81 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
91.0/ 1001,547 ratings across the index network
c.okafor97/100
Line quoted that three comparable suppliers declined to quote. Material returned within specification. Independent verification of individual lots still required.
r.yildiz95/100
Retention time assigned to the principal peak, printed. Figures as reported by the named service. Not reproduced by the index.
c.zamora99/100
Custom synthesis delivered 3 days inside the quoted schedule at the specified purity. Peptide content 96.9%. Not medical advice.
r.onwuka99/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. Supplementary certificate produced without demur. Research use. Not approved for human administration.
d.vogel98/100
Supplementary certificate for a lot released 15 months earlier retrieved from supplier records on request. Further submissions on later lots would improve coverage.
t.kaufmann96/100
Fill uniformity: 9 units weighed against declared fill, all within 2%. No excipient. Cake intact.
r.duarte95/100
Repeat determination at 6 months: 97.7%. Original: 97.7%. No drift detected in this sample. Price list and lead time arrived in the same reply as the specification sheet. Submitted to the index in full.
d.lindholm96/100
Cold chain intact. Phase-change pack solid at arrival, day 6.
h.weiss95/100
Published stock status matched availability. Same-day dispatch. Peptide content 97.1%.
t.sandvik99/100
Release signed and dated, named individual. Supplementary certificate produced without demur. No adverse observation.
m.danquah100/100
Tracking number live from despatch and accurate at every hop. Contributor declares no interest beyond the transaction.
f.tulloch97/100
Residual-solvent screen included unrequested. Evidence base adequate for a rating on this criterion.
z.mensa98/100
Consistency: 7 lots, purity band under 1.0 points wide. n=1, declared as n=1.
m.ogunleye95/100
Transit 7 days from stock held in the Netherlands against a quoted 7. Customs documentation correct at first presentation.
em.varga100/100
Dispatch on the quoted day through a public holiday week. Documentation complete at first issue. Independent verification of individual lots still required.
no.laurent98/100
Lot GLB-26-774 submitted to Medutest. Declared 97.5%, reported 97.8%. Delta inside method repeatability. Supplementary certificate produced without demur.
h.kuipers99/100
Reconstitution of tesamorelin 2 mg: clear on contact, no haze, no particulate. Not medical advice.
d.perrin96/100
Certificate carries batch traceability back to the synthesis run. Complete against the index minimum data set at first issue.
s.wikstrom97/100
7 orders, 8 months. No substitution, no reformulation, no post-payment unavailability. Bulk break points published rather than negotiated, and the invoice matched the published step.
g.varga100/100
Nine orders, tracking live and accurate on each. Record covers the lots named. Not generalised.
b.stanescu98/100
Documentation complete at first issue. No supplementary request raised. Peptide content 96.9%. Submitted to the index in full.
f.ramos97/100
Counter-ion identity and content answered quantitatively, one working day. Signature and release date present. Not medical advice.
an.silva96/100
Peptide content reported separately from chromatographic purity across all 12 certificates held. Documentation practice, not a single purity figure, is the substance here.
l.falk100/100
Dispatch inside the quoted window. Material returned 98.8%. No excipient. Cake intact.
o.mensa99/100
Packing: a cold pack that was still solid when the box was opened. Contributor declares no interest beyond the transaction.
Block 12
Most recent records
Block 13
Contributor annotations on GL Biochem records 183
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on GL Biochem material are below, each linked to the record it sits on.
The match requires at least four named impurities, same identities, same rank order, levels agreeing within 0.05 % area or 10 % relative. A totals-only certificate cannot be fingerprinted at all.
Ordering under an unremarkable name and address is the whole method. It requires no cooperation from anybody and it produces the strongest evidence this index holds.
Manufacturer-tier and reseller-tier material can be the same bulk at very different prices and very different minimum quantities. The fingerprint is the only public evidence that the two are related.
A supplier's water-system qualification would make a burden estimate possible without measuring every lot. No such document exists in this market as far as the index can tell.
Resolution scales with the square root of plate count and linearly with selectivity. Shallowing the gradient changes selectivity, which is the more effective of the two levers on a close pair.
Quantitative NMR would give absolute content independent of the balance and let the two be cross-checked. On a record like this the balance is already closed; the cross-check would test the assumption behind it.
The index grades identity by instrument class, not by the ppm figure alone: "confirmed" where the determination was made at high resolution, "consistent with" where it was not. The status block above says which applies to this record, and it is worth reading before the number.
Two instruments or it is not confirmed, and this record is one instrument. It is a good one instrument, and the index records it as confirmed rather than corroborated for that reason.
Every annotation the index holds on GL Biochem material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what GL Biochem itself publishes, open glbiochem.net → alongside.
Block 14
Where to buy GL Biochem
GL Biochem (Shanghai) Ltd. sells direct from glbiochem.net. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the GL Biochem store at glbiochem.net →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.